Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.

https://phgkb.cdc.gov/GAPPKB/phgHome.do

From From Genomics & Health Impact Scan Database

This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.

---

• Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.  
  Kowalec Kaarina et al. BMJ open 2017 Jun 7(5) e016276
• The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).  
  O'Connor Cormac T et al. Expert opinion on drug metabolism & toxicology 2017 Jun
• All Scientific Hands on Deck to End the Opioid Crisis  
  N Volkov and F Collins, NIH Blog, May 31, 2017
• Pharmacogenomics for personalized pain medicine.  
  Ko Tai-Ming et al. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists 2016 Mar 54(1) 24-30
• Tramadol Therapy and CYP2D6 Genotype  
  L Dean, NCBI 2015

more